Idorsia launches QUVIVIQ (daridorexant) in Switzerland – a first-in-class treatment for chronic insomnia disorder to improve both nighttime symptoms and daytime functioning

QUVIVIQ™ is indicated for the treatment of adult patients with insomnia, characterized by symptoms present for at least three months and considerable impact on daytime functioningQUVIVIQ,... | June 12, 2023

Related Keywords

Allschwil ,Switzerland General ,Switzerland ,United States ,Japan ,United Kingdom ,Italy ,Germany ,Canada ,Austria ,Great Britain ,Swiss ,American ,Alice Huisman ,Andrewc Weiss ,J Clin Pharmacol ,Jean Paul Clozel ,Santa Monica ,American Psychiatric Association ,European Commission ,Idorsia Pharmaceuticals Ltd ,Drug Administration ,Head Of Investor Relations Corporate Communications ,Idorsia Ltd ,Swiss Exchange ,International Study ,University Of Pittsburg ,Health Canada ,European Commission Decision Reliance Procedure ,Regulatory Agency ,Paul Clozel ,Chief Executive Officer ,General Manager ,Idorsia Switzerland ,Lancet Neurology ,Patient Information ,Full Prescribing ,European Commission Decision Reliance ,Insomnia Daytime Symptoms ,Impacts Questionnaire ,Statistical Manual ,Mental Disorders ,Discov Today Dis ,Clin Sleep ,Economic Burden ,Idorsia Pharmaceuticals ,Vice President ,Investor Relations ,Pharmaceuticals Ltd ,